Recently, an exciting result in phase II clinical trial shows that the co-administration of PF-0522134 (a new ACC1 inhibitor in clinical trial) and PF-6865571 (DGAT2 inhibitor) has a strong effect in treating NASH without the side effect of hypertriglyceridemia (113). This evidence concerns the gene DGAT2 and metabolic dysfunction-associated steatohepatitis.